Eisai (ESAIY) and Biogen (BIIB) announced an update on the ongoing regulatory review of the Marketing Authorization Application, MAA, for ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

Request To Download Free Sample of This Strategic Report @- However, high cost of instruments and lack of trained professionals impede the market growth. Epigenetics is a stream of genetics that ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discov ...